Abstract：
BACKGROUND: It is well-known that oral surgical procedures pose a high risk for medication-related osteonecrosis of the jaw in patients taking bisphosphonates. Although some position papers and guidelines have been published with regard to its treatment, few studies have investigated prevention methods. This study investigates the effectiveness of methenolone enanthate, an anabolic steroid, for the prevention of medication-related osteonecrosis of the jaw.
METHODS: Thirty-six Wistar rats were divided into three groups. Two experimental groups, Z and ZM, took zoledronic acid for 6 weeks prior to extraction of the left maxillary first molar. The Group ZM also was given methenolone enanthate continuously for 1 week before and 4 weeks after the extraction. The control group was not given any medication. The rats were euthanized 5 weeks after extraction. The extraction socket was evaluated clinically for bone exposure and histologically for inflammation, hyperemia, collagen fibers, epithelialization, number of osteoclasts, and empty lacunae.
RESULTS: Six rats died during the experimental research. The bone exposure rate, mean numbers of attached osteoclasts (in 40× magnification), and empty lacunae (in 100× magnification) were 0%, 4%, and 0.8% in Group C; 75%, 1%, and 8% in Group Z; and 10%, 2.1%, and 3% in Group ZM, respectively. Significant differences exist between all groups regarding the number of empty lacunae. There were significant differences between Group C/ZM and Group Z in terms of bone exposure rate, inflammation, hyperemia, collagen fiber organization, and epithelialization.
CONCLUSIONS: In our tested preclinical model, methenolone enanthate has shown potential for preventing medication-related osteonecrosis of the jaw.
METHODS: Thirty-six Wistar rats were divided into three groups. Two experimental groups, Z and ZM, took zoledronic acid for 6 weeks prior to extraction of the left maxillary first molar. The Group ZM also was given methenolone enanthate continuously for 1 week before and 4 weeks after the extraction. The control group was not given any medication. The rats were euthanized 5 weeks after extraction. The extraction socket was evaluated clinically for bone exposure and histologically for inflammation, hyperemia, collagen fibers, epithelialization, number of osteoclasts, and empty lacunae.
RESULTS: Six rats died during the experimental research. The bone exposure rate, mean numbers of attached osteoclasts (in 40× magnification), and empty lacunae (in 100× magnification) were 0%, 4%, and 0.8% in Group C; 75%, 1%, and 8% in Group Z; and 10%, 2.1%, and 3% in Group ZM, respectively. Significant differences exist between all groups regarding the number of empty lacunae. There were significant differences between Group C/ZM and Group Z in terms of bone exposure rate, inflammation, hyperemia, collagen fiber organization, and epithelialization.
CONCLUSIONS: In our tested preclinical model, methenolone enanthate has shown potential for preventing medication-related osteonecrosis of the jaw.
摘要：
背景：众所周知，在服用双膦酸盐的患者中，口腔外科手术对药物相关的颌骨坏死构成高风险。尽管已经发表了一些关于其治疗的立场文件和准则，很少有研究调查预防方法。本研究调查了庚酸甲烯酮的有效性，合成代谢类固醇,用于预防药物相关的颌骨坏死。
方法：36只Wistar大鼠分为3组。两个实验组,Z和ZM，在拔除左上颌第一磨牙前服用唑来膦酸6周。ZM组还在提取前1周和提取后4周连续给予甲烯醇酮庚酸酯。对照组不给予任何药物治疗。在提取后5周将大鼠安乐死。对拔牙槽进行了骨暴露的临床评估和炎症的组织学评估，充血,胶原纤维，上皮化,破骨细胞的数量，和空的空洞。
结果：6只大鼠在实验研究中死亡。骨骼暴露率，附着破骨细胞的平均数量（放大40倍），空腔(放大100倍)为0%，4%,C组为0.8%；75%，1%,Z组为8%；10%，2.1%,ZM组为3%，分别。在空腔数方面，所有组之间存在显着差异。C/ZM组与Z组的骨暴露率差异有统计学意义,炎症,充血,胶原纤维组织，和上皮化。
结论：在我们测试的临床前模型中，甲烯醇酮庚酸酯已显示出预防与药物相关的颌骨坏死的潜力。
方法：36只Wistar大鼠分为3组。两个实验组,Z和ZM，在拔除左上颌第一磨牙前服用唑来膦酸6周。ZM组还在提取前1周和提取后4周连续给予甲烯醇酮庚酸酯。对照组不给予任何药物治疗。在提取后5周将大鼠安乐死。对拔牙槽进行了骨暴露的临床评估和炎症的组织学评估，充血,胶原纤维，上皮化,破骨细胞的数量，和空的空洞。
结果：6只大鼠在实验研究中死亡。骨骼暴露率，附着破骨细胞的平均数量（放大40倍），空腔(放大100倍)为0%，4%,C组为0.8%；75%，1%,Z组为8%；10%，2.1%,ZM组为3%，分别。在空腔数方面，所有组之间存在显着差异。C/ZM组与Z组的骨暴露率差异有统计学意义,炎症,充血,胶原纤维组织，和上皮化。
结论：在我们测试的临床前模型中，甲烯醇酮庚酸酯已显示出预防与药物相关的颌骨坏死的潜力。
